Provided by Tiger Trade Technology Pte. Ltd.

NEWAMSTERDAM PHARMA CO NV

21.26
-0.8700-3.93%
Pre-market: 21.280.0200+0.09%07:28 EDT
Volume:1.67M
Turnover:35.37M
Market Cap:2.54B
PE:-9.91
High:22.13
Open:22.00
Low:20.91
Close:22.13
52wk High:42.21
52wk Low:20.91
Shares:119.54M
Float Shares:90.76M
Volume Ratio:1.19
T/O Rate:1.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1442
EPS(LYR):-1.7211
ROE:-36.81%
ROA:-20.11%
PB:4.02
PE(LYR):-12.35

Loading ...

NewAmsterdam PREVAIL Interim Faces 'Considerable' Risk, RBC Says

MT Newswires Live
·
Oct 05

RBC Cuts Price Target on NewAmsterdam Pharma to $42 From $50, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Oct 05

13D Filings

Dow Jones
·
Oct 03

NewAmsterdam Pharma CSO Johannes Jacob Pieter Kastelein Reports $1,257,659 Share Disposal

Reuters
·
Oct 03

NewAmsterdam Pharma Grants 71,800 Inducement Stock Options to New Hires at USD 24.16 Per Share

Reuters
·
Oct 03

Analysts Are Bullish on Top Healthcare Stocks: Invivyd (IVVD), NewAmsterdam Pharma Company (NAMS)

TIPRANKS
·
Sep 30

NewAmsterdam Pharma Doses First Patient in Phase 2b Spinoza Trial of Obicetrapib in Preclinical Alzheimer’s Disease

Reuters
·
Sep 29

Menarini Group & Newamsterdam Pharma Receive European Commission Approval for Ubeslo and Evlarco

Reuters
·
Sep 22

Analysts Have Conflicting Sentiments on These Healthcare Companies: NewAmsterdam Pharma Company (NAMS) and Lipocine (LPCN)

TIPRANKS
·
Sep 22

NewAmsterdam Pharma Gets EU Approval for Ubeslo, Evlarco

MT Newswires Live
·
Sep 21

NewAmsterdam Pharma Price Target Maintained with a $52.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 08

Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN), NewAmsterdam Pharma Company (NAMS) and Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Sep 08

Why the Dow is Being Dragged Down by a Swiss Company's Bad News

Dow Jones
·
Sep 08

Novartis Cholesterol Setback Tests Hopes for Emerging Heart Disease Drugs

Reuters
·
Sep 07

Newamsterdam Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Reuters
·
Sep 04

NewAmsterdam Pharma Grants Inducement Share Options for 52,900 Shares at $24.92 Each

Reuters
·
Sep 04

NewAmsterdam Pharma to Present Phase 3 Obicetrapib Trial Data at ESC Congress 2026

Reuters
·
Aug 26

NewAmsterdam Pharma CSO Johannes Kastelein Disposes of 125,000 Shares for USD 3.36 Million

Reuters
·
Aug 26

NewAmsterdam Pharma Amends 8-K to Disclose COO Douglas Kling Separation, Advisor Agreement Terms

Reuters
·
Aug 15

NewAmsterdam Pharma Appoints Robert Gunning Principal Accounting Officer

Reuters
·
Aug 15